NCT00210899View on ClinicalTrials.gov

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

828

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Skin Diseases, InfectiousSkin Diseases, BacterialStaphylococcal Skin Infections
Interventions
DRUG

ceftobiprole medocaril

DRUG

Vancomycin plus Ceftazidime

Sponsors
All Listed Sponsors
lead

Basilea Pharmaceutica

INDUSTRY

NCT00210899 - Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections | Biotech Hunter | Biotech Hunter